Racial disparities in breast cancer treatment patterns and treatment related adverse events.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 01 2023
22 01 2023
Historique:
received:
14
09
2022
accepted:
04
01
2023
entrez:
22
1
2023
pubmed:
23
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
The main objective of this work was to perform a comprehensive analysis and provide a race-stratified epidemiological report accounting for differences in treatment patterns and treatment related adverse events in Non-Hispanic women with breast cancer (BC). The cohort included women ≥ 18 years diagnosed with in-situ, early-stage, and late-stage BC (2005-2022). Treatment patterns included: surgery, breast radiation, chemotherapy, endocrine therapy, or biologic therapy. Treatment related adverse events were: chemotherapy complications, cardiovascular toxicities, immune-related adverse events, psychological affectations, or cognitive decline/dementia. The influence of race on the outcomes was measured via Cox proportional-hazards models. We included 17,454 patients (82% non-Hispanic Whites [NHW]). Most of the patients had a Charlson Comorbidity Score between 1 and 2 (68%), and TNM stage I (44.5%). Surgery was performed in 51.5% of the cases, while 30.6% received radiotherapy, 26.4% received chemotherapy, 3.1% received immunotherapy, and 41.2% received endocrine therapy. Non-Hispanic Blacks (NHB) had a lower probability of undergoing breast cancer surgery (aHR = 0.92, 95% CI 0.87-0.97) and of being prescribed endocrine therapy (aHR = 0.83, 95% CI 0.79-0.89), but a higher probability of receiving adjuvant radiotherapy (aHR = 1.40, 95% CI 1.29-1.52). Moreover, NHBs had lower risk of being diagnosed with psychological issues (aHR = 0.71, 95% CI 0.63-0.80) but a higher risk for cognitive decline/dementia (aHR = 1.30, 95% CI 1.08-1.56). In conclusion, NHB women diagnosed with BC were less likely than NHW to undergo curative intent surgery or receive endocrine therapy, and had a higher risk of cognitive decline/dementia after cancer treatment. Public policy measures are urgently needed which equalize access to quality healthcare for all patients and that promote a learning healthcare system which can improve cancer outcomes.
Identifiants
pubmed: 36683066
doi: 10.1038/s41598-023-27578-4
pii: 10.1038/s41598-023-27578-4
pmc: PMC9868122
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233Informations de copyright
© 2023. The Author(s).
Références
Am J Epidemiol. 2001 Aug 15;154(4):299-304; discussion 305-6
pubmed: 11495851
J Alzheimers Dis. 2021;80(3):1129-1138
pubmed: 33646162
J Community Health. 2019 Dec;44(6):1224-1252
pubmed: 31273620
Breast Cancer Res Treat. 2003 Sep;81(1):21-31
pubmed: 14531494
Am J Public Health. 2012 May;102(5):936-44
pubmed: 22420803
Surg Oncol Clin N Am. 2012 Jul;21(3):417-37, viii
pubmed: 22583991
Cancer Causes Control. 2009 Nov;20(9):1681-8
pubmed: 19688184
Acta Oncol. 2011 Feb;50(2):187-93
pubmed: 21231780
Adv Exp Med Biol. 2019;1152:31-49
pubmed: 31456178
Cancer. 2008 Feb 15;112(4):900-8
pubmed: 18181101
Med Care. 2016 Aug;54(8):765-71
pubmed: 27116106
Med Care. 2021 Oct 1;59(10):901-906
pubmed: 34387620
CA Cancer J Clin. 2015 May-Jun;65(3):221-38
pubmed: 25960198
Clin Med Insights Pathol. 2015 Dec 21;8:23-31
pubmed: 26740749
J Clin Oncol. 2009 Feb 10;27(5):713-9
pubmed: 19103731
Sci Rep. 2022 Mar 28;12(1):5248
pubmed: 35347189
Oncologist. 2013;18(9):986-93
pubmed: 23939284
Crit Rev Oncol Hematol. 2010 Oct;76(1):44-52
pubmed: 19800812
PLoS One. 2015 Sep 23;10(9):e0138511
pubmed: 26398658
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
Clin Breast Cancer. 2005 Aug;6(3):260-6; discussion 267-9
pubmed: 16137438
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Commun. 2018 Oct 16;9(1):4181
pubmed: 30327465
Infect Control Hosp Epidemiol. 2014 Oct;35 Suppl 3:S10-6
pubmed: 25222888
JAMA. 2013 Jul 24;310(4):389-97
pubmed: 23917289
BMC Public Health. 2019 Mar 28;19(1):346
pubmed: 30922286
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Am Soc Clin Oncol Educ Book. 2021 Jun;41:e29-e46
pubmed: 34161138
Cancer Med. 2018 Jun;7(6):2710-2717
pubmed: 29733543
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
Am J Public Health. 2015 Dec;105(12):e60-76
pubmed: 26469668
Lancet. 2021 May 8;397(10286):1750-1769
pubmed: 33812473
J Womens Health (Larchmt). 2008 Jul-Aug;17(6):923-30
pubmed: 18554094
J Pain Symptom Manage. 2017 Aug;54(2):245-258.e2
pubmed: 28533160
Br J Cancer. 2021 Jan;124(2):315-332
pubmed: 32901135
Am Behav Sci. 2013 Aug 1;57(8):
pubmed: 24347666
Am J Med. 2005 May;118(5):529-35
pubmed: 15866256
N Engl J Med. 2001 Jun 28;344(26):1997-2008
pubmed: 11430330
JAMA. 2015 Jan 13;313(2):165-73
pubmed: 25585328
J Clin Oncol. 2022 Jan 1;40(1):8-11
pubmed: 34694897
J Racial Ethn Health Disparities. 2015 Dec;2(4):527-36
pubmed: 26863559
Oncol Rev. 2012 Jan 30;6(1):e2
pubmed: 25992204
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Racial Ethn Health Disparities. 2018 Feb;5(1):117-140
pubmed: 28275996
N Engl J Med. 2004 Aug 5;351(6):575-84
pubmed: 15295050
N Engl J Med. 2022 Jun 23;386(25):2349-2352
pubmed: 35713541
J Clin Oncol. 2007 Jun 20;25(18):2522-7
pubmed: 17577029
J Clin Oncol. 2015 Nov 1;33(31):3621-7
pubmed: 26371147
Arch Intern Med. 2003 Jan 13;163(1):49-56
pubmed: 12523916
Ann Surg Oncol. 2018 Jul;25(7):1783-1785
pubmed: 29671136
Arch Public Health. 2016 Dec 5;74:50
pubmed: 27980734
JTO Clin Res Rep. 2022 Mar 09;3(4):100307
pubmed: 35400080
Breast Cancer Res Treat. 2008 Jun;109(3):545-57
pubmed: 17659438
Cancer. 2010 Feb 1;116(3):734-41
pubmed: 20014181
JAMA Netw Open. 2022 Mar 1;5(3):e220573
pubmed: 35230441
Nat Rev Cancer. 2015 Apr;15(4):248-54
pubmed: 25673085
J Clin Oncol. 2006 Mar 20;24(9):1357-62
pubmed: 16549830